[go: up one dir, main page]

WO2012122533A3 - Compositions and methods related to antibodies to staphylococcal proteins isda or isdb - Google Patents

Compositions and methods related to antibodies to staphylococcal proteins isda or isdb Download PDF

Info

Publication number
WO2012122533A3
WO2012122533A3 PCT/US2012/028618 US2012028618W WO2012122533A3 WO 2012122533 A3 WO2012122533 A3 WO 2012122533A3 US 2012028618 W US2012028618 W US 2012028618W WO 2012122533 A3 WO2012122533 A3 WO 2012122533A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
isdb
antibodies
methods related
isda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/028618
Other languages
French (fr)
Other versions
WO2012122533A2 (en
Inventor
Hwan Keun Kim
Andrea DEDENT
Carla EMOLO
Dominique M. Missiakas
Olaf Schneewind
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of WO2012122533A2 publication Critical patent/WO2012122533A2/en
Publication of WO2012122533A3 publication Critical patent/WO2012122533A3/en
Priority to US13/959,147 priority Critical patent/US20140037650A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody, such as a recombinant antibody, that binds IsdA and/or IsdB polypeptides.
PCT/US2012/028618 2009-07-24 2012-03-09 Compositions and methods related to antibodies to staphylococcal proteins isda or isdb Ceased WO2012122533A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/959,147 US20140037650A1 (en) 2009-07-24 2013-08-05 Compositions and methods related to antibodies to staphylococcal proteins isda or isdb

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451471P 2011-03-10 2011-03-10
US61/451,471 2011-03-10
US201161526166P 2011-08-22 2011-08-22
US61/526,166 2011-08-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US84281110A Continuation-In-Part 2009-07-24 2010-07-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/959,147 Continuation US20140037650A1 (en) 2009-07-24 2013-08-05 Compositions and methods related to antibodies to staphylococcal proteins isda or isdb

Publications (2)

Publication Number Publication Date
WO2012122533A2 WO2012122533A2 (en) 2012-09-13
WO2012122533A3 true WO2012122533A3 (en) 2012-11-22

Family

ID=46798849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/028618 Ceased WO2012122533A2 (en) 2009-07-24 2012-03-09 Compositions and methods related to antibodies to staphylococcal proteins isda or isdb

Country Status (1)

Country Link
WO (1) WO2012122533A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013000097B1 (en) 2010-07-02 2022-02-01 The University Of Chicago Isolated immunogenic polypeptide, immunogenic composition and its use
CN112867732A (en) * 2018-11-21 2021-05-28 瑞泽恩制药公司 Anti-staphylococcal antibodies and uses thereof
PH12021552903A1 (en) 2019-06-11 2022-04-04 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN112920259A (en) * 2021-02-05 2021-06-08 中国人民解放军陆军军医大学 IsdB epitope peptide for diagnosing or preventing staphylococcus aureus infection and application thereof
CN120943954A (en) * 2025-10-20 2025-11-14 重庆原伦生物科技有限公司 Preparation and application of anti-staphylococcus aureus IsdB antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20080095777A1 (en) * 2004-09-22 2008-04-24 Glaxosmithkline Biologicals S.A. Immunogenic Composition for Use in Vaccination Against Staphylococcei
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095777A1 (en) * 2004-09-22 2008-04-24 Glaxosmithkline Biologicals S.A. Immunogenic Composition for Use in Vaccination Against Staphylococcei
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, H. K. ET AL.: "IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge", VACCINE, vol. 28, 10 March 2010 (2010-03-10), pages 6382 - 6392 *

Also Published As

Publication number Publication date
WO2012122533A2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
WO2014059442A8 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2012177658A3 (en) Methods of treating and preventing staphylococcus aureus infections and associated conditions
BR112013020500A2 (en) isolated, recombinant or purified antibody
WO2012145491A3 (en) Composition and method for enhancing an immune response
WO2011130650A3 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2012034077A3 (en) Compositions and methods related to attenuated staphylococcal strains
CY1118875T1 (en) Antibiotic Antibiotics
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2008019162A3 (en) Compositions and methods related to staphylococcal bacterium proteins
HK1207654A1 (en) Modified antibody regions and uses thereof
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2010008423A (en) Treatment of microbial infections.
HK1207321A1 (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2012122533A3 (en) Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
WO2014085749A3 (en) Antibodies against clostridium difficile
WO2015145250A3 (en) Expression of a single chain antibody against salmonella in lactobacillus
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
NZ774893A (en) Type iii secretion system targeting molecules
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies
WO2014044793A3 (en) Cd22-binding peptides
WO2017137954A3 (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12755002

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12755002

Country of ref document: EP

Kind code of ref document: A2